A newly approved drug may help in the battle against Clostridium difficile — a potentially fatal “superbug” gut infection that has become a scourge in U.S. hospitals. In two clinical trials, researchers found that the drug, called bezlotoxumab (Zinplava), cut the risk of a recurrent C. difficile infection by almost 40 percent. That’s important, because the gut infection commonly comes back after treatment with antibiotics — around 20 percent of the time, according to the U.S. Centers for Disease Control and Prevention. Read more.
HealthDay News, January 25, 2017